EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

Teleflex’s second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significantly year over year. Management attributed the quarter’s results primarily to strong execution in its Vascular and Surgical businesses, as well as accelerated progress on its strategic transformation plan. CEO Jason Weidman cited robust demand for hemostatic and ligation products but acknowledged that performance in the Interventional segment

In early August 2026, Teleflex Incorporated reported second-quarter results showing higher sales of US$570.33 million but lower net income of US$99.69 million year-on-year, cut its 2026 earnings guidance, completed a US$250 million repurchase of 1,900,000 shares, and affirmed a quarterly US$0.34 dividend payable on September 30, 2026. The mix of revenue growth alongside weaker earnings, extended integration timelines for the Vascular Intervention acquisition, and active balance sheet...

Teleflex stock has rebounded in the short term yet still sits far below its level of five years ago, while the valuation checks send mixed signals as a Discounted Cash Flow (DCF) estimate points to upside and market multiples lean the other way. Over the past 5 years, Teleflex shares have declined 62.1%, which puts the current valuation in the context of a long and painful reset for investors. Completion of the US$1.5b OEM business sale and planned debt reduction and buybacks can support the...

CEO Weidman discusses integration delays, FDA approvals, and capital allocation strategy.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

TFX vs. PEN: Which Stock Is the Better Value Option?

Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Teleflex (NYSE:TFX) reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated integration of its acquired Vascular Intervention business weighed on Interventional results. Revenue f

Teleflex (TFX) shares moved on Interventional headwinds and the related 2026 revenue guidance revisi

Teleflex Inc (TFX) beats Q2 expectations but lowers full-year guidance due to slower-than-expected vascular intervention integration, while advancing key product milestones and capital returns.

While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teleflex (TFX) delivered earnings and revenue surprises of +37.50% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company Teleflex (NYSE:TFX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 28.9% year on year to $570.3 million. Its non-GAAP profit of $1.76 per share was 37.4% above analysts’ consensus estimates.

Teleflex (TFX) is drawing fresh investor attention after two closely timed moves. The company secured FDA approval for its EZPLAZ Freeze Dried Plasma and completed a US$1.5b OEM divestiture that refocuses its portfolio. See our latest analysis for Teleflex. Teleflex's recent FDA approval and the US$1.5b OEM sale come as the stock shows building momentum, with a 90 day share price return of 13.71% and a 1 year total shareholder return of 23.40%, despite weaker outcomes over three and five...

TransMedics (TMDX) delivered earnings and revenue surprises of -12.00% and +3.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) delivered earnings and revenue surprises of +14.75% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?